$486 Million is the total value of Cormorant Asset Management, LP's 65 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 42.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $121,074,000 | +784.1% | 507,500 | +144.6% | 24.90% | +586.2% |
| RCPT | Buy | RECEPTOS INC | $46,502,000 | +128.0% | 748,700 | +56.4% | 9.56% | +77.0% |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $16,056,000 | +9.2% | 100,000 | 0.0% | 3.30% | -15.2% | |
| DYAX | Sell | DYAX CORP | $15,180,000 | -12.2% | 1,500,000 | -16.7% | 3.12% | -31.8% |
| KERX | New | KERYX BIOPHARMACEUTICALS | $13,750,000 | – | 1,000,000 | +100.0% | 2.83% | – |
| KPTI | KARYOPHARM THERAPEUTICS INC | $13,452,000 | -24.9% | 385,000 | 0.0% | 2.77% | -41.7% | |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $13,320,000 | +199.3% | 850,000 | +183.3% | 2.74% | +132.4% |
| ARWR | ARROWHEAD RESH CORP | $13,293,000 | +3.2% | 900,000 | 0.0% | 2.73% | -19.9% | |
| XLRN | Buy | ACCELERON PHARMA INC | $12,096,000 | +78.0% | 400,000 | +100.0% | 2.49% | +38.2% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $10,758,000 | -27.8% | 1,100,000 | -5.8% | 2.21% | -43.9% |
| AKBA | AKEBIA THERAPEUTICS INC | $8,852,000 | -20.4% | 400,000 | 0.0% | 1.82% | -38.2% | |
| OVAS | New | OVASCIENCE INC | $8,569,000 | – | 516,200 | +100.0% | 1.76% | – |
| TSRO | TESARO INC | $8,076,000 | -13.5% | 300,000 | 0.0% | 1.66% | -32.8% | |
| DXCM | DEXCOM INC | $7,998,000 | +0.8% | 200,000 | 0.0% | 1.64% | -21.7% | |
| BMY | New | BRISTOL MYERS SQUIBB CO | $7,677,000 | – | 150,000 | +100.0% | 1.58% | – |
| OMER | Sell | OMEROS CORP | $6,969,000 | -64.3% | 547,900 | -51.2% | 1.43% | -72.3% |
| CMRX | Sell | CHIMERIX INC | $6,905,000 | +4.9% | 250,000 | -16.7% | 1.42% | -18.6% |
| GEVA | New | SYNAGEVA BIOPHARMA CORP | $6,878,000 | – | 100,000 | +100.0% | 1.42% | – |
| RARE | ULTRAGENYX PHARMACEUTICAL INC | $6,792,000 | +26.1% | 120,000 | 0.0% | 1.40% | -2.1% | |
| NVAX | NOVAVAX INC | $6,255,000 | -9.7% | 1,500,000 | 0.0% | 1.29% | -29.9% | |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $6,135,000 | – | 100,000 | +100.0% | 1.26% | – |
| HRTX | HERON THERAPEUTICS INC | $5,831,000 | -32.4% | 700,000 | 0.0% | 1.20% | -47.5% | |
| ARDX | New | ARDELYX INC | $5,523,000 | – | 388,700 | +100.0% | 1.14% | – |
| PTCT | Sell | PTC THERAPEUTICS INC | $5,501,000 | +40.3% | 125,000 | -16.7% | 1.13% | +8.9% |
| ACRX | Buy | ACELRX PHARMACEUTICALS INC | $5,490,000 | -23.5% | 1,000,000 | +42.9% | 1.13% | -40.6% |
| NKTR | New | NEKTAR THERAPEUTICS | $5,432,000 | – | 450,000 | +100.0% | 1.12% | – |
| SGMO | SANGAMO BIOSCIENCES INC | $5,393,000 | -29.4% | 500,000 | 0.0% | 1.11% | -45.2% | |
| CBPO | Sell | CHINA BIOLOGIC PRODS INC | $5,126,000 | +15.3% | 95,000 | -5.0% | 1.05% | -10.5% |
| EGRX | EAGLE PHARMACEUTICALS INC | $5,060,000 | -11.7% | 400,000 | 0.0% | 1.04% | -31.5% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $5,056,000 | -13.4% | 200,000 | 0.0% | 1.04% | -32.7% | |
| QTNT | QUOTIENT LTD | $4,715,000 | +12.8% | 500,000 | 0.0% | 0.97% | -12.5% | |
| SRNE | SORRENTO THERAPEUTICS INC | $4,520,000 | -33.0% | 1,000,000 | 0.0% | 0.93% | -48.0% | |
| ALKS | ALKERMES PLC | $4,287,000 | -14.8% | 100,000 | 0.0% | 0.88% | -33.9% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $3,905,000 | +23.6% | 50,000 | 0.0% | 0.80% | -4.1% | |
| VSAR | VERSARTIS INC | $3,798,000 | -32.3% | 200,000 | 0.0% | 0.78% | -47.4% | |
| RMTI | ROCKWELL MED INC | $3,656,000 | -23.8% | 400,000 | 0.0% | 0.75% | -40.8% | |
| ARRY | ARRAY BIOPHARMA INC | $3,570,000 | -21.7% | 1,000,000 | 0.0% | 0.73% | -39.2% | |
| IMDZ | New | IMMUNE DESIGN CORP | $3,532,000 | – | 200,000 | +100.0% | 0.73% | – |
| NSTG | NANOSTRING TECHNOLOGIES INC | $3,282,000 | -26.8% | 300,000 | 0.0% | 0.68% | -43.2% | |
| GLYC | GLYCOMIMETICS INC | $3,278,000 | -17.7% | 472,300 | 0.0% | 0.67% | -36.1% | |
| KIN | Buy | KINDRED BIOSCIENCES INC | $3,238,000 | +73.7% | 350,000 | +250.0% | 0.67% | +34.8% |
| CLVS | CLOVIS ONCOLOGY INC | $3,175,000 | +9.5% | 70,000 | 0.0% | 0.65% | -15.0% | |
| KITE | New | KITE PHARMA INC | $2,850,000 | – | 100,000 | +100.0% | 0.59% | – |
| GNVC | GENVEC INC | $2,765,000 | -19.1% | 1,329,300 | 0.0% | 0.57% | -37.1% | |
| ASPX | AUSPEX PHARMACEUTICALS INC | $2,567,000 | +15.3% | 100,000 | 0.0% | 0.53% | -10.5% | |
| GALT | Sell | GALECTIN THERAPEUTICS INC | $2,266,000 | -79.5% | 450,400 | -43.7% | 0.47% | -84.1% |
| AAVL | New | AVALANCHE BIOTECHNOLOGIES IN | $2,222,000 | – | 65,000 | +100.0% | 0.46% | – |
| REPH | Buy | RECRO PHARMA INC | $2,072,000 | -48.3% | 700,000 | +40.0% | 0.43% | -59.8% |
| AGEN | Sell | AGENUS INC | $2,022,000 | -30.2% | 650,000 | -27.8% | 0.42% | -45.8% |
| AQXP | AQUINOX PHARMACEUTICALS INC | $1,998,000 | -29.4% | 300,000 | 0.0% | 0.41% | -45.2% | |
| ZSPH | New | ZS PHARMA INC | $1,962,000 | – | 50,000 | +100.0% | 0.40% | – |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $1,902,000 | -36.8% | 150,000 | 0.0% | 0.39% | -51.0% | |
| CERU | CERULEAN PHARMA INC | $1,899,000 | -27.2% | 450,000 | 0.0% | 0.39% | -43.5% | |
| CLTX | Buy | CELSUS THERAPEUTICS PLCsponsored adr ne | $1,491,000 | +133.3% | 244,500 | +137.4% | 0.31% | +81.7% |
| RGLS | REGULUS THERAPEUTICS INC | $1,366,000 | -15.0% | 200,000 | 0.0% | 0.28% | -34.0% | |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $1,177,000 | – | 530,000 | +100.0% | 0.24% | – |
| ADXS | New | ADVAXIS INC | $1,176,000 | – | 350,000 | +100.0% | 0.24% | – |
| AGTC | Sell | APPLIED GENETIC TECHNOL CORP | $1,128,000 | -77.7% | 60,600 | -72.3% | 0.23% | -82.7% |
| AGRX | AGILE THERAPEUTICS INC | $1,095,000 | -16.3% | 150,000 | 0.0% | 0.22% | -35.2% | |
| NERV | New | MINERVA NEUROSCIENCES INC | $1,059,000 | – | 175,000 | +100.0% | 0.22% | – |
| New | BRISTOL MYERS SQUIBB CO | $985,000 | – | 5,000 | +100.0% | 0.20% | – | |
| CRIS | CURIS INC | $846,000 | -24.2% | 600,000 | 0.0% | 0.17% | -41.2% | |
| SCYX | SCYNEXIS INC | $739,000 | -7.9% | 100,000 | 0.0% | 0.15% | -28.6% | |
| SAGE | New | SAGE THERAPEUTICS INC | $315,000 | – | 10,000 | +100.0% | 0.06% | – |
| CLRBW | New | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $318,000 | – | 530,000 | +100.0% | 0.06% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.30% | – |
| Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -5,000 | -100.0% | -1.19% | – | |
| MRK | Exit | MERCK & CO INC NEW | $0 | – | -100,000 | -100.0% | -1.53% | – |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -90,000 | -100.0% | -1.91% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -200,000 | -100.0% | -4.55% | – |
| QCOR | Exit | QUESTCOR PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -4.90% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.